Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
polatuzumab vedotin + rituximab + dexamethasone + cytarabine + cisplatin
- Development stage
- Discontinued
- Lead developer
- Genentech
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Administration
- Intravenous, Oral
01
Overview
Polatuzumab vedotin + rituximab + dexamethasone + cytarabine + cisplatin is a multi-agent chemotherapy and immunotherapy regimen under investigation for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and other aggressive B-cell lymphomas. Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b on B cells; it delivers the microtubule inhibitor monomethyl auristatin E (MMAE) to malignant cells[1][2]. Rituximab is a monoclonal antibody against CD20 on B lymphocytes. Dexamethasone is a synthetic glucocorticoid with anti-inflammatory and immunosuppressive effects. Cytarabine is an antimetabolite that inhibits DNA synthesis. Cisplatin is a platinum-based chemotherapeutic agent that crosslinks DNA to induce apoptosis in rapidly dividing cells. This combination aims to maximize antitumor activity by leveraging multiple mechanisms of action.
- Other names
- polatuzumab vedotin-piiqanti-CD79b antibody-drug conjugateanti-CD-79b antibody-drug conjugateanti-CD 79b antibody-drug conjugateMMAE-conjugated anti-CD79b antibody
02
Targets
CD20 (B-lymphocyte antigen CD20)B-cell antigen receptor complex-associated protein beta chainGR (Glucocorticoid receptor)DNA polymerase family
Beyond the preview
Go deeper on polatuzumab vedotin + rituximab + dexamethasone + cytarabine + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on polatuzumab vedotin + rituximab + dexamethasone + cytarabine + cisplatin.